ai3Bio

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

ai3Bio - overview

Location

-, -, US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and founded in 2025, ai3Bio is a biotechnology company that research and develops immunology-based therapies for autoimmune diseases through its platforms use lipid nanoparticle (LNP)/mRNA and antibody technologies to identify and eliminate disease-causing T cells directly in vivo, aiming to restore immune balance at the source of disease. In September 2026, ai3Bio raised USD 37. 05 million in Series A funding co-led by UPMC Enterprises and Ziff Capital Partners, with participation from Cockrell Interests and Tanis Venture Management. ai3Bio develops preclinical therapeutics for patients with autoimmune diseases.


Its STARx platform uses lipid nanoparticles to deliver mRNA instructions that prompt pathogenic Th17 cells to self-destruct. Its T Deplete platform uses targeted antibodies to recruit the immune system to clear those cells. An AI discovery platform analyzes diseased tissue and supports target identification.


Current Investors

Cockrell Interests, Ziff Capital Partners, Tanis Venture Management, UPMC Enterprises

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare IT

Website

www.ai3.bio

Verticals

Artificial Intelligence, HealthTech, Nanotechnology, Research (Non-Medical)

Company Stage

Series A

Total Amount Raised

Subscriber access only

ai3Bio - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Series ACompletedai3Bio-

Displaying 1 - 1 of 1

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.